Analysts at Mizuho initiated coverage on Rite Aid Corporation. The firm set a “buy” rating and a price target of $10.
The action comes after the retail drugstore chain released its fourth quarter results last month. The company stated earnings of 12 cents per share on revenue of $6.86 billion, beating the consensus estimate of 7 cents per share on revenue of $6.79 billion.
During the same quarter the previous year, the company posted earnings of 6 cents per share on revenue of $6.6 billion.
Rite Aid Corporation, through its auxiliaries, operates a chain of retail drugstores in the United States. The company sells prescription drugs and a range of other merchandise, counting over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products.
In an opening trade, Shares of eBay Inc. (NASDAQ:EBAY), gained 0.85%, and is now trading at $61.08, hitting its highest level.
StubHub, an eBay company (EBAY), declared the top 10 hottest concerts of the summer, as determined by sales and demand drawn from its more than 16 million visitors and nearly 10 million live events per month: Taylor Swift overwhelmingly takes the #1 spot, nearly tripling the demand of One Direction in the #2 spot.
TOP 10 SUMMER CONCERTS:
As determined by total sales on StubHub for dates from Memorial Day through Labor Day
- Taylor Swift
- One Direction
- Grateful Dead (with only five total dates!)
- The Rolling Stones
- Kenny Chesney
- Ed Sheeran
- Billy Joel
- Foo Fighters
eBay Inc. operates as a technology company that enables commerce and payments on behalf of users, merchants, retailers, and brands of various sizes in the United States and internationally. It operates in three segments: Marketplaces, Payments, and Enterprise.
Shares of StemCells Inc. (NASDAQ:STEM), during its Friday’s current trading session fell -0.30%, and is now trading at $0.69.
StemCells, offered a business update and stated financial results for the first quarter 2015.
“StemCells, Inc. continues to make great progress,” said Martin McGlynn, CEO of StemCells, Inc. “We have accomplished the enrollment of the first cohort in our Phase II Pathway StudyTM in cervical spinal cord injury. This cohort set medical history by successfully transplanting more neural stem cells into the human spinal cord than has ever been done formerly. Based on the timing of concluding cohort 1, we would expect to have interim six month results from this open label cohort accessible in the fourth quarter 2015. We will also be releasing top-line data from both of our Phase I/II studies shortly. Data from our thoracic spinal cord injury study will be released at the 4th ISCoS/ASIA Joint Scientific Meeting in May. Data from our dry age related macular degeneration study will be released in June at the 2015 ISSCR Annual Meeting.”
StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system.
Finally, Hovnanian Enterprises Inc. (NYSE:HOV), lost -1.19% Friday.
Hovnanian Enterprises, will release financial results for the second quarter ended April 30, 2015 the morning of Tuesday, June 9, 2015. The Company will webcast its second quarter earnings conference call at 11:00 a.m. (ET) on Tuesday, June 9, 2015.
Hovnanian Enterprises, Inc. designs, constructs, markets, and sells residential homes in the United States. It constructs single-family detached homes, attached townhomes and condominiums, urban infill, and active adult homes.
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
This article was originally published on WS News Publishers at the following link … Current Movers: Rite Aid Corporation (NYSE:RAD), eBay Inc. (NASDAQ:EBAY), StemCells Inc. (NASDAQ:STEM), Hovnanian Enterprises Inc. (NYSE:HOV)